Charles Schwab Investment Management Inc Stoke Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $557 Billion
- Q2 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 340,779 shares of STOK stock, worth $10.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
340,779
Previous 310,307
9.82%
Holding current value
$10.8 Million
Previous $2.06 Million
87.45%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding STOK
# of Institutions
144Shares Held
57MCall Options Held
2.7KPut Options Held
57.4K-
Black Rock Inc. New York, NY5.41MShares$171 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.4MShares$171 Million18.16% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$162 Million0.89% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$147 Million0.53% of portfolio
-
Redmile Group, LLC San Francisco, CA4.38MShares$139 Million6.04% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $1.25B
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...